OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) On Upward Trajectory


OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is adding a nice bump today after a strong opening to the trading week yesterday. OWCP is on an upward trajectory after some summer doldrums.

OWCP gained 22.6% in Monday’s trading session to end the day at $0.429 a share. While the stock is up by more than 15% for the year, it has underperformed after dropping from $2.60 a share in March.

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) casts itself as a company that engages in the research and development of Cannabis-based medical products. The company provides medical products for the treatment of various medical conditions and/or diseases, such as multiple myeloma, psoriasis, PTSD, and migraines; and delivery systems. It also provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations.

OWCP through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals, treatments and unique delivery systems for the effective delivery and dosage of medical cannabis.

All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.

OWCP’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.

The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. The company was formerly known as Dynamic Applications Corp. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Petach Tikva, Israel.

Find out when $OWCP stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

OWCP has already completed a preclinical efficacy study in psoriasis. The study indicating a 70% reduction in biological markers related to the condition. “As a management team, it is our vision to develop OWC Pharma as the leading cannabis-based specialty Pharma Company. Over the last few months we have executed on a number of important steps in order to fulfill this vision,” said Mr. Bignitz.

OWCP is well positioned to deploy its capital towards growth and is also looking into cross-listing on the TSX as a way of increasing its shares liquidity. The company’s subsidiary has also been active in protecting IP. he company’s wholly owned subsidiary, One World Cannabis, has filed a patent application with the European Union Patent and Trademark Office for an active cannabinoid-based psoriasis topical cream. “Our primary short-term objective is to introduce our topical cream for skin conditions including, most importantly, psoriasis to the market,” said Mr. Bignitz.

With a market cap of $64.38M, OWCP has a chunk ($2M) of cash on the books, which stands against about $300K in total current liabilities. Monday’s rally helped suspend a sell-off wave that had plagued the stock in recent months. This is an exciting story, and we look forward to a follow-up chapter as events transpire. For continuing coverage on shares of $OWCP stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $OWCP, either long or short, and we have not been compensated for this article.